Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR 주식 보고서

시가총액: US$25.8m

Citius Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Citius Pharmaceuticals의 수입은 연평균 -19.6%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 증가했습니다(1.2%).

주요 정보

-19.6%

수익 성장률

31.0%

EPS 성장률

Pharmaceuticals 산업 성장6.0%
매출 성장률n/a
자기자본 수익률-44.4%
순이익n/a
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01
Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Jul 05

Critical Care Biopharma - Citius Pharmaceuticals

Apr 13

Citius: 2022 Is A Year Of Catalysts

Mar 28

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

수익 및 비용 분석

Citius Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqCM:CTXR 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 240-402912
31 Mar 240-372613
31 Dec 230-392514
30 Sep 230-342215
30 Jun 230-311816
31 Mar 230-311717
31 Dec 220-281616
30 Sep 220-341618
30 Jun 220-311516
31 Mar 220-291513
31 Dec 210-261312
30 Sep 210-251112
30 Jun 210-241111
31 Mar 210-21912
31 Dec 200-21912
30 Sep 200-1899
30 Jun 200-1789
31 Mar 200-1789
31 Dec 190-1679
30 Sep 190-1679
30 Jun 190-1578
31 Mar 190-1276
31 Dec 180-1368
30 Sep 180-1377
30 Jun 180-1375
31 Mar 180-1385
31 Dec 170-1182
30 Sep 170-1073
30 Jun 170-1074
31 Mar 170-1165
31 Dec 160-954
30 Sep 160-853
30 Jun 160-732
31 Mar 160-422
31 Dec 150-312
30 Sep 150-312
30 Jun 150-321
31 Mar 150-211
31 Dec 140-210
30 Sep 140-110
30 Jun 140-100
31 Mar 140-100

양질의 수익: CTXR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: CTXR 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: CTXR 은(는) 수익성이 없으며 지난 5년 동안 연간 19.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 CTXR 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: CTXR 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 54.6% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: CTXR 현재 수익성이 없기 때문에 마이너스 자본 수익률( -44.38% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기